Fundraising Fox
/Companies
Sign in

Galena Biopharma

NASDAQ: SLS

San Ramon, US · Delaware corporation

Find your way into Galena Biopharma

Sign up to see every warm intro you have to Galena Biopharma

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Galena Biopharma team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Galena Biopharma is a clinical-stage biopharmaceutical company developing cancer immunotherapies and small-molecule oncology drugs, including galinpepimut-S, a peptide immunotherapy targeting the WT1 antigen in multiple cancer types, and SLS009, a selective CDK9 inhibitor for hematologic and solid tumors.

Biotech

Founders & leadership

MW
Mark W. Schwartz, Ph.D.Executive
BN
Bijan Nejadnik, M.D.Executive
TJ
Thomas J. KnappExecutive
RD
Ryan DunlapExecutive
BH
Brian Hamilton, M.D., Ph.D.Executive
MJ
Mark J. Ahn, Ph.D.Executive
AM
Angelos M. StergiouPresident, Chief Executive Officer and Director
DC
Dragan CicicSenior Vice President, Chief Development Officer
JT
John T. BurnsSenior Vice President, Chief Financial Officer

Board

SA
Steven A. KriegsmanBoard director
WL
William L. AshtonBoard director
SJ
Sanford J. HillsbergBoard director

Reported raises · per SEC filings

Form D private placements

$60.6M disclosed across 4 of 6 rounds · 1900–2024

▶$18.4MraisedMar 2024 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jane WasmanDirector
  • Angelos M. StergiouExecutive Officer, Director
  • David A. ScheinbergDirector
  • John T. BurnsExecutive Officer
  • John VarianDirector
  • Robert Van NostrandDirector
  • Katherine Bach KalinDirector
Offering amount
$18.4M
Amount sold
$18.4M
Sales commissions
$1.4M
Finders' fees
$60K
Placement agents
A.G.P./Alliance Global Partners
First sale
Mar 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.2MraisedAug 2020 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert L. Van NostrandDirector
  • John T. BurnsExecutive Officer
  • David A. ScheinbergDirector
  • John VarianDirector
  • Barbara A. WoodExecutive Officer
  • Angelos M. StergiouExecutive Officer, Director
  • Jane WasmanDirector
Offering amount
$9.2M
Amount sold
$9.2M
Sales commissions
$584.1K
Placement agents
Maxim Group LLC
First sale
Jul 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.1MraisedJul 2016 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • William L. AshtonDirector
  • John T. BurnsExecutive Officer
  • Sanford J. HillsbergDirector
  • Mary Ann GrayDirector
  • Thomas J. KnappExecutive Officer
  • Richard ChinDirector
  • Irving M. EinhornDirector
  • Stephen GallikerDirector
  • Mark W. SchwartzExecutive Officer, Director
  • Bijan NejadnikExecutive Officer
  • Rudolph NisiDirector
Offering amount
$9.1M
Amount sold
$9.1M
Sales commissions
$793K
Placement agents
Raymond James & Associates, Inc.
First sale
Jul 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$24MraisedMay 2016 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark W. Schwartz, Ph.D.Director
  • William L. AshtonDirector
  • Sanford J. HillsbergDirector
  • Rudolph Nisi, M.D.Director
  • Richard Chin, M.D.Director
  • Bijan Nejadnik, M.D.Executive Officer
  • Stephen GallikerDirector
  • Steven A. KriegsmanDirector
  • Mary Ann Gray, Ph.D.Director
  • Thomas J. KnappExecutive Officer
  • Irving M. EinhornDirector
Offering amount
$24M
Amount sold
$24M
Sales commissions
$240K
Placement agents
Trump Securities, LLC
First sale
May 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶Undisclosed amountofferedJan 2014 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Richard Chin, M.D.Director
  • Mark W. Schwartz, Ph.D.Executive Officer
  • Ryan DunlapExecutive Officer
  • Stephen S. GallikerDirector
  • William L. AshtonDirector
  • Rudolph Nisi, M.D.Director
  • Steven A. KriegsmanDirector
  • Brian Hamilton, M.D., Ph.D.Executive Officer
  • Mark J. Ahn, Ph.D.Executive Officer, Director
  • Sanford J. HillsbergDirector
First sale
Jan 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$15.4Mvaluation at IPOJul 2018 · $2.09/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Frequently asked questions

What does Galena Biopharma do?
Galena Biopharma is a clinical-stage biopharmaceutical company developing cancer immunotherapies and small-molecule oncology drugs, including galinpepimut-S, a peptide immunotherapy targeting the WT1 antigen in multiple cancer types, and SLS009, a selective CDK9 inhibitor for hematologic and solid tumors.
How much funding has Galena Biopharma raised?
Galena Biopharma has disclosed $60.6M raised across 4 of its 6 known rounds.
Where is Galena Biopharma headquartered?
Galena Biopharma is headquartered in San Ramon, US.